This final report published in NEJM about the efficacy of remdesivir against COVID-19 infection vs placebo showed its superiority though only in soft end points, which does not seem to modify the course of this pandemic. Multiple drugs initially promising have been shown ineffective against the new virus. The case of hydroxychloroquine resulted paradigmatic: not<a href="https://solaci.org/en/2020/11/02/efficacy-of-remdesivir-against-covid-19/" title="Read more" >...</a>
The benefits of intravascular ultrasound (IVUS) guidance in all angioplasties with second-generation drug-eluting stents (DES) persist through 3 years of follow-up. These data derive from the extended follow-up of the ULTIMATE study, presented virtually at TCT 2020 and published simultaneously in JACC Intv. At 3 years, target-vessel failure remained lower in patients whose angioplasty was guided by<a href="https://solaci.org/en/2020/10/22/tct-2020-our-next-goal-should-be-using-ivus-guidance-in-every-angioplasty/" title="Read more" >...</a>
Patients with a bigger number of complex anatomical characteristics that increase PCI complexity have worse results at one-year followup. These data come from a large multicenter study (e-Ultimaster) recently published in EuroIntervention. The more complex the characteristics, the greater the increase in events. It is important to see past the obvious anatomical challenges (bifurcations, calcification,<a href="https://solaci.org/en/2020/10/14/complex-pci-complex-characteristics-impact-results/" title="Read more" >...</a>
01- ESC 2020 | New European Guidelines on Non-ST-Segment Elevation Acute Coronary Syndromes: What’s New? The new European guidelines on NON-ST-segment elevation acute coronary syndromes (NSTE ACS) were presented virtually during the European Society of Cardiology 2020 Congress (ESC 2020) and published in Eur Heart J. Read more HERE 02- Ticagrelor to Improve Venous Graft Patency Saphenous<a href="https://solaci.org/en/2020/10/09/the-most-read-articles-of-september-in-interventional-cardiology/" title="Read more" >...</a>
The size of the original bioprosthetic valve impacts long term mortality, as does the type of bioprosthetic valve used in percutaneous reinterventions. The number of patients with failed bioprosthesis is on the rise, mainly due to increased life expectancy. Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) has become more and more common these days and<a href="https://solaci.org/en/2020/09/29/size-does-matter-for-long-term-viv/" title="Read more" >...</a>
The risk of contrast induced kidney injury is significantly lower in patients receiving transcatheter aortic valve replacement (TAVR) compared against patients getting a coronary angiography or angioplasty. This is true even for valvular heart disease patients with higher risk profiles. Differences in contrast-induced acute kidney injury between TAVR or coronary patients had not been previously<a href="https://solaci.org/en/2020/09/16/same-contrast-dose-different-risk-of-kidney-injury-depending-on-procedure/" title="Read more" >...</a>
Moderate or severe left ventricle outflow tract calcification increases the risk of annulus rupture, residual aortic regurgitation and the need for a second valve. This recent study analyzed the performance of different contemporary prosthetic valves in patients with this particular anatomy. Since the early days of transcatheter aortic valve replacement (TAVR) outflow tract calcification has<a href="https://solaci.org/en/2020/09/10/outflow-tract-calcification-and-the-best-valve-in-this-context/" title="Read more" >...</a>
New guidelines for the diagnosis and treatment of atrial fibrillation (AF) were released at the 2020 European Society of Cardiology (ESC) virtual congress. This document incorporates several findings from the latest clinical trials, but also represents a great shift in terms of how physicians from different specialties should classify and manage arrhythmia after confirming the<a href="https://solaci.org/en/2020/09/08/esc-2020-2020-atrial-fibrillation-guidelines-news-on-diagnosis-classification-and-care/" title="Read more" >...</a>
Data of this “real world” study have confirmed that diabetic patients with multivessel disease will benefit from coronary artery bypass grafting (CABG). According to Dr. Douglas S. Lee, main author of this study, the evidence is fairly conclusive, enough to recommend CABG as first option in this particular subgroup of patients similar to FREEDOM patients. <a href="https://solaci.org/en/2020/09/07/esc-2020-at-long-term-diabetic-patients-benefit-from-surgery/" title="Read more" >...</a>
Trimetazidine in addition to optimal medical therapy in patients undergoing coronary PCI does not change events rate at long term. The ATPCI study was presented at ESC 2020 and simultaneously published in the Lancet. This study randomized coronary PCI patients with stable or acute NSTEMI coronary syndromes to trimetazidine vs. placebo. What is the rationale<a href="https://solaci.org/en/2020/09/07/esc-2020-post-pci-trimetazidine-no-adverse-events-or-great-benefits/" title="Read more" >...</a>